Herein we describe the synthesis and evaluation of four novel HER2-targeting, cathepsin B-
sensitive antibody–drug conjugates bearing a monomethylauristatin E (MMAE) cytotoxic …

Antibody–drug conjugates (ADCs) constitute an emerging class of anticancer agents that
deliver potent payloads selectively to tumors while avoiding systemic toxicity associated with …

As the antibody drug conjugate (ADC) community continues to shift towards site-specific
conjugation technology, there is a growing need to understand how the site of conjugation …

Antibody–drug conjugates (ADCs) have become an important therapeutic modality for
oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the …

In the context of antibody–drug conjugates (ADCs), noncleavable linkers provide a means to
deliver cytotoxic small molecules to cell targets while reducing systemic toxicity caused by …

Antibody-drug conjugates (ADCs) hold great therapeutic promise for cancer indications;
however, treating tumors with intratumor heterogeneity remains challenging. We …

Systemic chemotherapy, the current standard of care for the treatment of cancer, is rarely
curative and is often accompanied by debilitating side effects. Targeted drug delivery stands …

Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer
therapeutics with ten clinical approvals to date. As the field matures, much attention has …

It is becoming increasingly clear that site-specific conjugation offers significant advantages
over conventional conjugation chemistries used to make antibody–drug conjugates (ADCs) …

Despite the advances in the design of antibody–drug conjugates (ADCs), the search is still
ongoing for novel approaches that lead to increased stability and homogeneity of the ADCs …